CVS Health (CVS) AI Stock Analysis
CVS Health
(BMV:CVS)
No summary available
CVS Health (CVS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 115.43B
- Dividend Yield
- 2.92%
- Average Volume (3M)
- 1,046
- Price to Earnings (P/E)
- 23.6
- Beta (1Y)
- 0.02
- Revenue Growth
- -2.20%
- EPS Growth
- -9.61%
- Country
- Mexico
- Employees
- 259,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
CVS Health Business Overview & Revenue Model
Company Description
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Hea...
CVS Health Earnings Call Summary
The call conveyed strong operational and financial momentum across segments with material upside: double-digit growth in operating income, raised EPS guidance, improved cash flow outlook, specialty leadership, and early tangible AI-driven efficiencies. Offsetting these positives are notable industry-specific headwinds—most prominently near-term 340B pressures, anticipated Caremark membership declines in 2027, ongoing reimbursement and regulatory pressures, and some timing-related pull-forwards. Management emphasized disciplined execution, balance sheet improvement and a multi-year growth outlook (mid-teens EPS CAGR through 2028), while acknowledging and preparing for specific near-term headwinds.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
CVS raised its full‑year 2026 outlook, increasing adjusted EPS guidance to $7.90–$8.10 (up $0.60, ~+8%), raising expected cash flow from operations to at least $11.5B (up ~$2B), and targeting total revenues of at least $414B; enterprise adjusted operating income is now expected to be $16.58–$16.92B, Health Care Benefits adjusted operating income $5.03–$5.37B (up >$1B), with an expected MBR of 89.75% ±25 bps, Pharmacy & Consumer Wellness adjusted operating income at least $6.4B (up $220M) and Health Services outlook reiterated; management noted Q2 results of $5.2B adjusted operating income and $2.58 adjusted EPS, YTD cash flow from operations of ~$10.6B, parent cash of ~$2.7B and leverage of ~3.5x, said no share repurchases are assumed in the current outlook, expects second‑half EPS weighted to Q3, anticipates the Q1–Q4 MBR increase in Health Care Benefits to be slightly above 950 bps (adjusted for prior‑year development), reiterated a mid‑teens adjusted EPS CAGR for 2025–2028, and provided preliminary 2027 context implying a reasonable floor of at least $8.44 (≈13% growth off a $7.46 adjusted baseline, excluding prior‑year development and individual‑exchange items).
CVS Health Risk Analysis
CVS Health disclosed 40 risk factors in its most recent earnings report. CVS Health reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksCVS Health Peers Comparison
Overall Rating
CI72Outperform
ELV69Neutral
CNC64Neutral
UNH62Neutral
HUM60Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CI | 72Outperform | $78.80B | 12.30 | 15.24% | 2.08% | 8.15% | 31.47% |
| ELV | 69Neutral | $90.76B | 17.89 | 11.59% | 1.64% | 3.60% | -4.06% |
| CNC | 64Neutral | $33.89B | 23.13 | 6.78% | ― | 9.71% | ― |
| UNH | 62Neutral | $365.29B | 23.23 | 16.10% | 2.23% | 3.33% | ― |
| HUM | 60Neutral | $49.77B | 38.92 | 6.91% | 0.85% | 18.33% | -18.53% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:CVS | CVS Health Corp | 1704.00 | 281.92 | 19.82% | |
| CNC | Centene | 68.45 | 32.34 | 89.56% | |
| CI | Cigna | 298.23 | 39.44 | 15.24% | |
| HUM | Humana | 414.50 | 136.26 | 48.97% | |
| UNH | Unitedhealth Group Inc. | 406.97 | 84.72 | 26.29% | |
| ELV | Elevance Health, Inc. | 420.07 | 109.62 | 35.31% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.